Raymond James & Associates’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $49.1M | Buy |
|
|||||
|
2024
Q2 | $51.3M | Sell |
|
|||||
|
2024
Q1 | $67.3M | Buy |
|
|||||
|
2023
Q4 | $57.6M | Sell |
|
|||||
|
2023
Q3 | $49.4M | Buy |
|
|||||
|
2023
Q2 | $51.8M | Buy |
|
|||||
|
2023
Q1 | $46.9M | Buy |
|
|||||
|
2022
Q4 | $48.7M | Sell |
|
|||||
|
2022
Q3 | $45.6M | Buy |
|
|||||
|
2022
Q2 | $26.6M | Buy |
|
|||||
|
2022
Q1 | $32.8M | Sell |
|
|||||
|
2021
Q4 | $80.5M | Buy |
|
|||||
|
2021
Q3 | $74.3M | Buy |
|
|||||
|
2021
Q2 | $63.4M | Buy |
|
|||||
|
2021
Q1 | $46.4M | Buy |
|
|||||
|
2020
Q4 | $32.5M | Buy |
|
|||||
|
2020
Q3 | $24.2M | Buy |
|
|||||
|
2020
Q2 | $16.3M | Buy |
|
|||||
|
2020
Q1 | $10.2M | Buy |
|
|||||
|
2019
Q4 | $11.5M | Buy |
|
|||||
|
2019
Q3 | $9.3M | Buy |
|
|||||
|
2019
Q2 | $8.2M | Buy |
|
|||||
|
2019
Q1 | $5.58M | Buy |
|
|||||
|
2018
Q4 | $3.65M | Buy |
|
|||||
|
2018
Q3 | $4.19M | Buy |
|
|||||
|
2018
Q1 | – | Sell |
|
|||||
|
2017
Q4 | $531K | Buy |
|
|||||
|
2017
Q3 | $434K | Buy |
|
|||||
|
2017
Q2 | $378K | Sell |
|
|||||
|
2017
Q1 | $496K | Buy |
|
|||||
|
2016
Q4 | – | Sell |
|
|||||
|
2016
Q3 | $2.54M | Buy |
|
|||||
|
2016
Q2 | $2.06M | Buy |
|
|||||
|
2015
Q4 | – | Sell |
|
|||||
|
2015
Q3 | $2.09M | Buy |
|
|||||
|
2015
Q2 | $1.56M | Buy |
|